Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2017

Open Access 01-12-2017 | Research article

Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: a network meta-analysis

Authors: Hai-Lin Zhang, Min Tan, Ai-Min Qiu, Zhang Tao, Chang-Hui Wang

Published in: BMC Pulmonary Medicine | Issue 1/2017

Login to get access

Abstract

Background

Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is the most common reason for the hospitalization and death of pulmonary patients. The use of antibiotics as adjuvant therapy for AECOPD, however, is still a matter of debate.

Methods

In this study, we searched the PubMed, EmBase, and Cochrane databases for randomized controlled trials published until September 2016 that evaluated the use of antibiotics for AECOPD treatment. The major outcome variables were clinical cure rate and adverse effects. The microbiological response rate, relapse of exacerbation, and mortality were also analysed. A random-effect network was used to assess the effectiveness and tolerance of each antibiotic used for AECOPD treatment.

Results

In this meta-analysis, we included 19 articles that assessed 17 types of antibiotics used in 5906 AECOPD patients. The cluster ranking showed that dirithromycin had a high clinical cure rate with a low rate of adverse effects. Ofloxacin, ciprofloxacin, and trimethoprim-sulfamethoxazole had high clinical cure rates with median rates of adverse effects. In terms of the microbiological response rate, only doxycycline was significantly better than placebo (odds ratio (OR), 3.84; 95% confidence interval (CI), 1.96–7.54; p < 0.001). There were no other significant results with respect to the frequency of recurrence or mortality.

Conclusions

Our study indicated that dirithromycin is adequate for improving the clinical cure rate of patients with AECOPD with few adverse effects. Ofloxacin, ciprofloxacin, and trimethoprim-sulfamethoxazole are also recommended for disease treatment. However, caution should still be exercised when using antibiotics to treat AECOPD.
Trial Registration Not applicable.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–73.CrossRefPubMed Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–73.CrossRefPubMed
2.
go back to reference Steiropoulos P, Tzouvelekis A, Bouros D. Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(2):205–15.PubMedPubMedCentral Steiropoulos P, Tzouvelekis A, Bouros D. Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(2):205–15.PubMedPubMedCentral
3.
go back to reference Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J. 2013;42(1):239–51.CrossRefPubMed Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J. 2013;42(1):239–51.CrossRefPubMed
4.
go back to reference Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–63.CrossRefPubMedPubMedCentral Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–63.CrossRefPubMedPubMedCentral
5.
go back to reference Hurst JR. Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(6):625–6.CrossRefPubMed Hurst JR. Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(6):625–6.CrossRefPubMed
6.
go back to reference Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355–65.CrossRefPubMed Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355–65.CrossRefPubMed
7.
go back to reference Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med. 2006;21(10):1011–9.CrossRefPubMedPubMedCentral Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med. 2006;21(10):1011–9.CrossRefPubMedPubMedCentral
8.
go back to reference Kiser TH, Vandivier RW. Severe acute exacerbations of chronic obstructive pulmonary disease: does the dosage of corticosteroids and type of antibiotic matter? Curr Opin Pulm Med. 2015;21(2):142–8.CrossRefPubMed Kiser TH, Vandivier RW. Severe acute exacerbations of chronic obstructive pulmonary disease: does the dosage of corticosteroids and type of antibiotic matter? Curr Opin Pulm Med. 2015;21(2):142–8.CrossRefPubMed
9.
go back to reference Ouanes I, Ouanes-Besbes L, Ben Abdallah S, Dachraoui F, Abroug F. Trends in use and impact on outcome of empiric antibiotic therapy and non-invasive ventilation in COPD patients with acute exacerbation. Ann Intensive Care. 2015;5(1):30.CrossRefPubMedPubMedCentral Ouanes I, Ouanes-Besbes L, Ben Abdallah S, Dachraoui F, Abroug F. Trends in use and impact on outcome of empiric antibiotic therapy and non-invasive ventilation in COPD patients with acute exacerbation. Ann Intensive Care. 2015;5(1):30.CrossRefPubMedPubMedCentral
10.
go back to reference Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;12:CD010257.PubMed Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;12:CD010257.PubMed
11.
go back to reference Soto FJ, Varkey B. Evidence-based approach to acute exacerbations of COPD. Curr Opin Pulm Med. 2003;9(2):117–24.CrossRefPubMed Soto FJ, Varkey B. Evidence-based approach to acute exacerbations of COPD. Curr Opin Pulm Med. 2003;9(2):117–24.CrossRefPubMed
12.
go back to reference Liu KX, Xu B, Wang J, Zhang J, Ding HB, Ariani F, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis. J Thorac Dis. 2014;6(3):221–9.PubMedPubMedCentral Liu KX, Xu B, Wang J, Zhang J, Ding HB, Ariani F, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis. J Thorac Dis. 2014;6(3):221–9.PubMedPubMedCentral
13.
go back to reference Ni W, Shao X, Cai X, Wei C, Cui J, Wang R, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One. 2015;10(3):e0121257.CrossRefPubMedPubMedCentral Ni W, Shao X, Cai X, Wei C, Cui J, Wang R, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One. 2015;10(3):e0121257.CrossRefPubMedPubMedCentral
14.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRefPubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRefPubMedPubMedCentral
15.
go back to reference Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.CrossRefPubMedPubMedCentral Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.CrossRefPubMedPubMedCentral
16.
go back to reference White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3(2):111–25.CrossRefPubMedPubMedCentral White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3(2):111–25.CrossRefPubMedPubMedCentral
17.
go back to reference Li D, Wang T, Shen S, Cheng S, Yu J, Zhang Y, et al. Effects of Fluroquinolones in newly diagnosed, sputum-positive tuberculosis therapy: a systematic review and network meta-analysis. PLoS One. 2015;10(12):e0145066.CrossRefPubMedPubMedCentral Li D, Wang T, Shen S, Cheng S, Yu J, Zhang Y, et al. Effects of Fluroquinolones in newly diagnosed, sputum-positive tuberculosis therapy: a systematic review and network meta-analysis. PLoS One. 2015;10(12):e0145066.CrossRefPubMedPubMedCentral
18.
go back to reference Trinquart L, Chatellier G, Ravaud P. Adjustment for reporting bias in network meta-analysis of antidepressant trials. BMC Med Res Methodol. 2012;12:150.CrossRefPubMedPubMedCentral Trinquart L, Chatellier G, Ravaud P. Adjustment for reporting bias in network meta-analysis of antidepressant trials. BMC Med Res Methodol. 2012;12:150.CrossRefPubMedPubMedCentral
19.
go back to reference Giusti M, Blasi F, Iori I, Mazzone A, Sgambato F, Politi C, et al. Prulifloxacin vs Levofloxacin for exacerbation of COPD after failure of other antibiotics. COPD. 2016;13(5):555–60.CrossRefPubMed Giusti M, Blasi F, Iori I, Mazzone A, Sgambato F, Politi C, et al. Prulifloxacin vs Levofloxacin for exacerbation of COPD after failure of other antibiotics. COPD. 2016;13(5):555–60.CrossRefPubMed
20.
go back to reference Rhee CK, Chang JH, Choi EG, Kim HK, Kwon YS, Kyung SY, et al. Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, phase III, non-inferiority trial. Int J Chron Obstruct Pulmon Dis. 2015;10:2265–75.CrossRefPubMedPubMedCentral Rhee CK, Chang JH, Choi EG, Kim HK, Kwon YS, Kyung SY, et al. Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, phase III, non-inferiority trial. Int J Chron Obstruct Pulmon Dis. 2015;10:2265–75.CrossRefPubMedPubMedCentral
21.
go back to reference Brusse-Keizer M, VanderValk P, Hendrix R, Kerstjens H, van der Palen J. Necessity of amoxicillin clavulanic acid in addition to prednisolone in mild-to-moderate COPD exacerbations. BMJ Open Respir Res. 2014;1(1):e000052.CrossRefPubMedPubMedCentral Brusse-Keizer M, VanderValk P, Hendrix R, Kerstjens H, van der Palen J. Necessity of amoxicillin clavulanic acid in addition to prednisolone in mild-to-moderate COPD exacerbations. BMJ Open Respir Res. 2014;1(1):e000052.CrossRefPubMedPubMedCentral
22.
go back to reference Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361–8.CrossRefPubMed Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361–8.CrossRefPubMed
23.
go back to reference Yoon HI, Lee CH, Kim DK, Park GM, Lee SM, Yim JJ, et al. Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:329–34.PubMedPubMedCentral Yoon HI, Lee CH, Kim DK, Park GM, Lee SM, Yim JJ, et al. Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:329–34.PubMedPubMedCentral
24.
go back to reference Blasi F, Schaberg T, Centanni S, Del Vecchio A, Rosignoli MT, Dionisio P. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis. Pulm Pharmacol Ther. 2013;26(5):609–16.CrossRefPubMed Blasi F, Schaberg T, Centanni S, Del Vecchio A, Rosignoli MT, Dionisio P. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis. Pulm Pharmacol Ther. 2013;26(5):609–16.CrossRefPubMed
25.
go back to reference Llor C, Moragas A, Hernandez S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(8):716–23.CrossRefPubMed Llor C, Moragas A, Hernandez S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(8):716–23.CrossRefPubMed
26.
go back to reference Wilson R, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J. 2012;40(1):17–27.CrossRefPubMed Wilson R, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J. 2012;40(1):17–27.CrossRefPubMed
27.
go back to reference Nouira S, Marghli S, Besbes L, Boukef R, Daami M, Nciri N, et al. Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. Clin Infect Dis. 2010;51(2):143–9.CrossRefPubMed Nouira S, Marghli S, Besbes L, Boukef R, Daami M, Nciri N, et al. Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. Clin Infect Dis. 2010;51(2):143–9.CrossRefPubMed
28.
go back to reference Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(2):150–7.CrossRefPubMed Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(2):150–7.CrossRefPubMed
29.
go back to reference Llor C, Hernandez S, Ribas A, Alvarez C, Cots JM, Bayona C, et al. Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care. Int J Chron Obstruct Pulmon Dis. 2009;4:45–53.PubMedPubMedCentral Llor C, Hernandez S, Ribas A, Alvarez C, Cots JM, Bayona C, et al. Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care. Int J Chron Obstruct Pulmon Dis. 2009;4:45–53.PubMedPubMedCentral
30.
go back to reference Andre-Alves MR, Jardim JR, Frare E, Silva R, Fiss E, Freire DN, Teixeira PJ. Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of chronic obstructive pulmonary disease. J Bras Pneumol. 2007;33(1):43–50.CrossRefPubMed Andre-Alves MR, Jardim JR, Frare E, Silva R, Fiss E, Freire DN, Teixeira PJ. Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of chronic obstructive pulmonary disease. J Bras Pneumol. 2007;33(1):43–50.CrossRefPubMed
31.
go back to reference Petitpretz P, Chone C, Tremolieres F. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int J Antimicrob Agents. 2007;30(1):52–9.CrossRefPubMed Petitpretz P, Chone C, Tremolieres F. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int J Antimicrob Agents. 2007;30(1):52–9.CrossRefPubMed
32.
go back to reference Lode H, Eller J, Linnhoff A, Ioanas M. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur Respir J. 2004;24(6):947–53.CrossRefPubMed Lode H, Eller J, Linnhoff A, Ioanas M. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur Respir J. 2004;24(6):947–53.CrossRefPubMed
33.
go back to reference Basyigit I, Yildiz F, Ozkara SK, Yildirim E, Boyaci H, Ilgazli A. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother. 2004;38(9):1400–5.CrossRefPubMed Basyigit I, Yildiz F, Ozkara SK, Yildirim E, Boyaci H, Ilgazli A. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother. 2004;38(9):1400–5.CrossRefPubMed
34.
go back to reference Castaldo RS, Celli BR, Gomez F, LaVallee N, Souhrada J, Hanrahan JP. A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Ther. 2003;25(2):542–57.CrossRefPubMed Castaldo RS, Celli BR, Gomez F, LaVallee N, Souhrada J, Hanrahan JP. A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Ther. 2003;25(2):542–57.CrossRefPubMed
35.
go back to reference Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet. 2001;358(9298):2020–5.CrossRefPubMed Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet. 2001;358(9298):2020–5.CrossRefPubMed
36.
go back to reference Umut S, Tutluoglu B, Aydin Tosun G, Musellim B, Erk M, Yildirim N, et al. Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor. Turkish thoracic society COPD working group. J Chemother. 1999;11(3):211–4.CrossRefPubMed Umut S, Tutluoglu B, Aydin Tosun G, Musellim B, Erk M, Yildirim N, et al. Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor. Turkish thoracic society COPD working group. J Chemother. 1999;11(3):211–4.CrossRefPubMed
37.
go back to reference Allegra L, Konietzko N, Leophonte P, Hosie J, Pauwels R, Guyen JN, et al. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study. J Antimicrob Chemother. 1996;37(Suppl A):93–104.CrossRefPubMed Allegra L, Konietzko N, Leophonte P, Hosie J, Pauwels R, Guyen JN, et al. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study. J Antimicrob Chemother. 1996;37(Suppl A):93–104.CrossRefPubMed
39.
go back to reference Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(4):356–61.CrossRefPubMed Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(4):356–61.CrossRefPubMed
40.
go back to reference MacNee W. Acute exacerbations of COPD. Swiss Med Wkly. 2003;133(17–18):247–57.PubMed MacNee W. Acute exacerbations of COPD. Swiss Med Wkly. 2003;133(17–18):247–57.PubMed
41.
go back to reference Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B, et al. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010;15(3):536–42.CrossRefPubMed Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B, et al. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010;15(3):536–42.CrossRefPubMed
42.
go back to reference Fromer L, Cooper CB. A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD. Int J Clin Pract. 2008;62(8):1219–36.CrossRefPubMed Fromer L, Cooper CB. A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD. Int J Clin Pract. 2008;62(8):1219–36.CrossRefPubMed
43.
go back to reference Sharma S, Anthonisen N. Role of antimicrobial agents in the management of exacerbations of COPD. Treat Respir Med. 2005;4(3):153–67.CrossRefPubMed Sharma S, Anthonisen N. Role of antimicrobial agents in the management of exacerbations of COPD. Treat Respir Med. 2005;4(3):153–67.CrossRefPubMed
44.
go back to reference Matera MG, Tufano MA, Polverino M, Rossi F, Cazzola M. Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease. Eur Respir J. 1997;10(1):98–103.CrossRefPubMed Matera MG, Tufano MA, Polverino M, Rossi F, Cazzola M. Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease. Eur Respir J. 1997;10(1):98–103.CrossRefPubMed
45.
go back to reference Bachmann K, Jauregui L, Sides G, Sullivan TJ. Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin. J Clin Pharmacol. 1993;33(9):861–5.CrossRefPubMed Bachmann K, Jauregui L, Sides G, Sullivan TJ. Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin. J Clin Pharmacol. 1993;33(9):861–5.CrossRefPubMed
46.
go back to reference Mensa J, Trilla A. Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones. Clin Microbiol Infect. 2006;12(Suppl 3):42–54.CrossRefPubMed Mensa J, Trilla A. Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones. Clin Microbiol Infect. 2006;12(Suppl 3):42–54.CrossRefPubMed
47.
go back to reference Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest. 2000;117(3):662–71.CrossRefPubMed Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest. 2000;117(3):662–71.CrossRefPubMed
48.
go back to reference Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–98.CrossRefPubMedPubMedCentral Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–98.CrossRefPubMedPubMedCentral
49.
go back to reference Bharti VK, Srivastava RS, Kumar H, Bag S, Majumdar AC, Singh G, et al. Effects of melatonin and epiphyseal proteins on fluoride-induced adverse changes in antioxidant status of heart, liver, and kidney of rats. Adv Pharmacol Sci. 2014;2014:532969.PubMedPubMedCentral Bharti VK, Srivastava RS, Kumar H, Bag S, Majumdar AC, Singh G, et al. Effects of melatonin and epiphyseal proteins on fluoride-induced adverse changes in antioxidant status of heart, liver, and kidney of rats. Adv Pharmacol Sci. 2014;2014:532969.PubMedPubMedCentral
50.
go back to reference Ducatelle R, Eeckhaut V, Haesebrouck F, Van Immerseel F. A review on prebiotics and probiotics for the control of dysbiosis: present status and future perspectives. Animal. 2015;9(1):43–8.CrossRefPubMed Ducatelle R, Eeckhaut V, Haesebrouck F, Van Immerseel F. A review on prebiotics and probiotics for the control of dysbiosis: present status and future perspectives. Animal. 2015;9(1):43–8.CrossRefPubMed
51.
go back to reference Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection. 2009;37(6):497–507.CrossRefPubMed Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection. 2009;37(6):497–507.CrossRefPubMed
52.
go back to reference Verduri A, Luppi F, D'Amico R, Balduzzi S, Vicini R, Liverani A, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS One. 2015;10(3):e0118241.CrossRefPubMedPubMedCentral Verduri A, Luppi F, D'Amico R, Balduzzi S, Vicini R, Liverani A, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS One. 2015;10(3):e0118241.CrossRefPubMedPubMedCentral
53.
go back to reference Cheng T, Gong Y, Guo Y, Cheng Q, Zhou M, Shi G, et al. Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials. Clin Respir J. 2013;7(4):305–18.CrossRefPubMed Cheng T, Gong Y, Guo Y, Cheng Q, Zhou M, Shi G, et al. Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials. Clin Respir J. 2013;7(4):305–18.CrossRefPubMed
54.
go back to reference Wang J, Nie B, Xiong W, Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther. 2012;37(2):204–11.CrossRefPubMed Wang J, Nie B, Xiong W, Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther. 2012;37(2):204–11.CrossRefPubMed
55.
go back to reference Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9(11):e113048.CrossRefPubMedPubMedCentral Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9(11):e113048.CrossRefPubMedPubMedCentral
56.
go back to reference Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24(137):451–61.CrossRefPubMed Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24(137):451–61.CrossRefPubMed
57.
go back to reference Van den Bruel A, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pulm Med. 2010;10:50.CrossRefPubMedPubMedCentral Van den Bruel A, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pulm Med. 2010;10:50.CrossRefPubMedPubMedCentral
Metadata
Title
Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: a network meta-analysis
Authors
Hai-Lin Zhang
Min Tan
Ai-Min Qiu
Zhang Tao
Chang-Hui Wang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2017
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-017-0541-0

Other articles of this Issue 1/2017

BMC Pulmonary Medicine 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.